Enanta Pharmaceuticals Inc (ENTA)


Stock Price Forecast

March 28, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Enanta Pharmaceuticals Inc chart...

About the Company

enanta pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. enanta is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis c virus (hcv). these inhibitors include members of the direct acting antiviral (daa) inhibitor classes – protease (partnered with abbvie), ns5a, and nucleotide polymerase – as well as a host-targeted antiviral (hta) inhibitor class targeted against cyclophilin. enanta’s lead protease inhibitor, paritaprevir, is part of abbvie’s recently approved hcv treatment regimen. in addition, enanta has a preclinical program in non-alcoholic steatohepatitis, or nash, which is a condition that results in liver inflammation and damage caused by a buildup of fat in the liver. enanta pharmaceuticals is a public company with offices in watertown, ma.

CEO

Jay Luly

Exchange

NASDAQ

Website

https://www.enanta.com/

$38M

Total Revenue

158

Employees

$369M

Market Capitalization

-2.65

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ENTA News

Enanta Pharmaceuticals gets grant for inhibiting coronavirus replication with compound of formula (i)

1h ago, source: Pharmaceutical Technology

Enanta Pharmaceuticals granted patent for compounds inhibiting coronavirus replication. Discover Formula (I) and its derivatives for treating virus infections.

Enanta Pharmaceuticals files patent for 17ß-HSD13 inhibitors for treating metabolic disease

16d ago, source: Pharmaceutical Technology

Discover Enanta Pharmaceuticals' groundbreaking patent for Formula (I) compounds as 17ß-HSD13 inhibitors, targeting metabolic diseases and liver conditions. Learn about the potential therapeutic ...

Buy Rating Affirmed for Hookipa Pharma on Emerging Oncology and Infectious Disease Pipelines

6d ago, source:

Roy Buchanan, an analyst from JMP Securities, reiterated the Buy rating on Hookipa Pharma (HOOK – Research Report). The associated price ...

Poseida spikes after FDA orphan status for CAR-T therapy

15d ago, source: Seeking Alpha

Update 9:40 PM EST: Adds comments from Poseida. Shares of Poseida Therapeutics (NASDAQ:PSTX) traded higher on Wednesday after ...

Madrigal climbs amid hopes for new NASH drug; B. Riley upgrades

on MSN ago, source:

Madrigal Pharmaceuticals (MDGL) stock surges as Wall Street welcomes the company's new NASH medication, Rezdiffra. Read more ...

Fusion Pharmaceuticals Inc

9mon ago, source:

View Fusion Pharmaceuticals Inc FUSN stock quote prices, financial information, real-time forecasts, and company news from CNN.

Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Arcellx Inc (ACLX) and Exact Sciences (EXAS)

14d ago, source: Business Insider

Skorney covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Enanta Pharmaceuticals ... See the top stocks recommended by analysts >> Arcellx Inc (ACLX) In a report ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...